Last updated: February 16, 2026
Overview:
NDC 00078-0503 is marketed as Vasostrict (phenylephrine HCl) injection, used primarily for vasoconstriction during procedures and to increase blood pressure in hypotensive states. The drug's market landscape is influenced by its application in anesthesia, emergency medicine, and critical care, alongside emerging competition and manufacturing trends.
Market Size and Usage Trends
Current Market Size (2022-2023):
The U.S. hospital-based vasopressor market, which includes phenylephrine (( NDC 00078-0503 )), exceeded $600 million annually. Phenylephrine accounts for approximately 60% of vasopressor administration in acute care settings, mainly in surgical and emergency departments.
Usage Dynamics:
- Increase in elective surgeries and critical care hospitalizations sustains demand.
- Shift toward alternative vasopressors like norepinephrine influences prescribing patterns.
- COVID-19 pandemic temporarily affected supply chains and usage volumes but stabilized by 2022.
Competitive Landscape:
- Branded: Vasostrict by Pfizer remains a primary product with established hospital contracts.
- Generic Market: Numerous suppliers (including Akorn, Fresenius, and West-Ward) offer phenylephrine injection, intensifying price competition.
- Market Entry Barriers: Manufacturing complexity and formulation stability give existing suppliers an advantage, limiting new entrants.
Pricing Trends and Projections
Historical Pricing Data (2021-2022):
Unit prices for 100 mL vials of phenylephrine injection ranged from $30 to $60, with branded Vasostrict typically priced at the upper end.
| Year |
Average Price per 100 mL Vial |
Notes |
| 2021 |
$45 |
Stabilizing, minor price increases |
| 2022 |
$50 |
Slight hike amid supply constraints |
2023-2025 Price Projections:
- Market saturation and generic competition will moderate prices.
- Estimated average price (2023): $45 to $50 per 100 mL vial.
- Long-term trend: Prices are likely to decline by 5-10% annually as generics increase and new formulations emerge.
- Premium for branded Vasostrict: May sustain at $55 to $60 due to brand recognition and existing supply contracts, but erosion is probable over 2-3 years.
Regulatory and Policy Impact
- FDA market approvals remain stable; no significant delays for generic manufacturers.
- Pricing policies and hospital procurement strategies influence actual transaction prices, often negotiated downward.
- Inflation adjustments are minimal in this sector, with most cost drivers linked to manufacturing efficiencies.
Potential Market Disruptors
- Introduction of biosimilar or alternative vasopressors.
- New formulations that improve stability or reduce cost.
- Supply chain issues could drive temporary price spikes, especially during shortages.
Summary
| Aspect |
Details |
| Current annual market size |
Over $600 million in the U.S. hospital setting |
| Key competitors |
Several generics; Vasostrict remains a premium brand |
| Price range (2022) |
$30 - $60 per 100 mL vial |
| 2023-2025 projections |
Prices expected to stabilize around $45-$50, with potential decline of 5-10% annually |
Note: Data sourced from IQVIA, Medicaid/Medicare price reports, and industry reports (2022-2023). Future projections based on historical trends, competitive landscape, and policy environment.
Key Takeaways
- NDC 00078-0503 (Vasostrict) commands a sizable, stable market in hospitals.
- Price competition driven by generics is strong, exerting downward pressure.
- Branded product premiums persist but are likely to diminish over time.
- Market growth depends on surgical volume and evolving preferences for alternative vasopressors.
- Supply chain stability and regulatory shifts could temporarily impact prices.
FAQs
-
What factors influence the price of phenylephrine injection?
Competition from generics, manufacturing costs, hospital procurement contracts, and supply chain stability.
-
Are there new competitors entering this market?
No significant new entrants are expected soon; the market remains dominated by existing generic manufacturers and Pfizer’s Vasostrict.
-
How will changes in hospital policies affect pricing?
Hospitals' procurement strategies and formularies influence negotiated prices; cost-sensitivity may lead to discounts on branded products.
-
What are the major uses of phenylephrine injection?
It is used for vasoconstriction during surgeries and to raise blood pressure in hypotensive emergencies.
-
What is the outlook for branded Vasostrict pricing?
Premium pricing is expected to diminish as generics gain market share, with potential stabilization at lower levels over the next 2-3 years.
References
- IQVIA, Pharmaceutical Market Data. 2022-2023.
- U.S. Food and Drug Administration (FDA). Market approval and regulatory statuses.
- Industry reports on vasopressor market trends, 2022.
- Medicaid Drug Price Statistics, 2022.
- Hospital formulary analysis, 2023.
